Marked regression of liver metastasis by combined therapy of ultrasound-mediated NFkB-decoy transfer and transportal injection of paclitaxel, in mouse

Haruhito Azuma, Naruya Tomita, Takeshi Sakamoto, Satoshi Kiyama, Teruo Inamoto, Kiyoshi Takahara, Yatsugu Kotake, Naoki Segawa, Ryuichi Morishita, Shiro Takahara, Hana Hayasaki, Yoshinori Otsuki, Shigeo Horie, Nobuhiko Tanigawa, Yoji Katsuoka

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Nuclear factor-kappaB (NFkB) plays a pivotal role in cancer progression. In this study, we developed a decoy cis-element oligodeoxyribonucleic acid against NFkB-binding site (NFkB-decoy), which effectively inhibits NFkB activity, and tested the effect of combined therapy comprising local transfection of NFkB-decoy into the liver and transportal injection of paclitaxel on cancer growth and metastasis using an orthotopic murine model of colon cancer liver metastasis. For NFkB-decoy transfection, we employed a novel approach using ultrasound exposure with an echocardiographic contrast agent, Optison. We examined the influence of NFkB-decoy transfer on susceptibility to paclitaxel in cancer cells and the mechanism involved using several in vitro analysis systems. We then studied the in vivo effect of combined NFkB-decoy transfer and paclitaxel in preventing cancer progression using a murine model of liver metastasis created by splenic injection of a human colon cancer cell line, HT29. In vitro experiments, including MTT-assay, fluorescence-activated cell sorter and cDNA array analysis, revealed that NFkB-decoy transfer significantly increased the susceptibility of cancer cells to paclitaxel, and that decreased expression of anti-apoptotic genes along with increased expression of genes relevant to the apoptosis-promotor may be involved. In vivo experiments showed that local transfection of NFkB-decoy into the liver followed by portal injection of paclitaxel effectively induced cancer cell apoptosis in the liver metastasis, and significantly prolonged animal survival compared to controls, without notable side effects. In conclusion, a combination of local NFkB-decoy transfer into the liver and transportal injection of paclitaxel may be a safe and effective new therapy for liver metastasis.

Original languageEnglish
Pages (from-to)1645-1656
Number of pages12
JournalInternational Journal of Cancer
Volume122
Issue number7
DOIs
Publication statusPublished - 01-04-2008
Externally publishedYes

Fingerprint

Paclitaxel
Neoplasm Metastasis
Injections
Liver
Transfection
Neoplasms
Colonic Neoplasms
Therapeutics
Apoptosis
Liver Neoplasms
Oligonucleotide Array Sequence Analysis
Contrast Media
Fluorescence
Binding Sites
Gene Expression
Cell Line
Acids
Growth
Genes

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Azuma, Haruhito ; Tomita, Naruya ; Sakamoto, Takeshi ; Kiyama, Satoshi ; Inamoto, Teruo ; Takahara, Kiyoshi ; Kotake, Yatsugu ; Segawa, Naoki ; Morishita, Ryuichi ; Takahara, Shiro ; Hayasaki, Hana ; Otsuki, Yoshinori ; Horie, Shigeo ; Tanigawa, Nobuhiko ; Katsuoka, Yoji. / Marked regression of liver metastasis by combined therapy of ultrasound-mediated NFkB-decoy transfer and transportal injection of paclitaxel, in mouse. In: International Journal of Cancer. 2008 ; Vol. 122, No. 7. pp. 1645-1656.
@article{54cb4a4f45ab437a82ee655b545d6ed7,
title = "Marked regression of liver metastasis by combined therapy of ultrasound-mediated NFkB-decoy transfer and transportal injection of paclitaxel, in mouse",
abstract = "Nuclear factor-kappaB (NFkB) plays a pivotal role in cancer progression. In this study, we developed a decoy cis-element oligodeoxyribonucleic acid against NFkB-binding site (NFkB-decoy), which effectively inhibits NFkB activity, and tested the effect of combined therapy comprising local transfection of NFkB-decoy into the liver and transportal injection of paclitaxel on cancer growth and metastasis using an orthotopic murine model of colon cancer liver metastasis. For NFkB-decoy transfection, we employed a novel approach using ultrasound exposure with an echocardiographic contrast agent, Optison. We examined the influence of NFkB-decoy transfer on susceptibility to paclitaxel in cancer cells and the mechanism involved using several in vitro analysis systems. We then studied the in vivo effect of combined NFkB-decoy transfer and paclitaxel in preventing cancer progression using a murine model of liver metastasis created by splenic injection of a human colon cancer cell line, HT29. In vitro experiments, including MTT-assay, fluorescence-activated cell sorter and cDNA array analysis, revealed that NFkB-decoy transfer significantly increased the susceptibility of cancer cells to paclitaxel, and that decreased expression of anti-apoptotic genes along with increased expression of genes relevant to the apoptosis-promotor may be involved. In vivo experiments showed that local transfection of NFkB-decoy into the liver followed by portal injection of paclitaxel effectively induced cancer cell apoptosis in the liver metastasis, and significantly prolonged animal survival compared to controls, without notable side effects. In conclusion, a combination of local NFkB-decoy transfer into the liver and transportal injection of paclitaxel may be a safe and effective new therapy for liver metastasis.",
author = "Haruhito Azuma and Naruya Tomita and Takeshi Sakamoto and Satoshi Kiyama and Teruo Inamoto and Kiyoshi Takahara and Yatsugu Kotake and Naoki Segawa and Ryuichi Morishita and Shiro Takahara and Hana Hayasaki and Yoshinori Otsuki and Shigeo Horie and Nobuhiko Tanigawa and Yoji Katsuoka",
year = "2008",
month = "4",
day = "1",
doi = "10.1002/ijc.23280",
language = "English",
volume = "122",
pages = "1645--1656",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

Azuma, H, Tomita, N, Sakamoto, T, Kiyama, S, Inamoto, T, Takahara, K, Kotake, Y, Segawa, N, Morishita, R, Takahara, S, Hayasaki, H, Otsuki, Y, Horie, S, Tanigawa, N & Katsuoka, Y 2008, 'Marked regression of liver metastasis by combined therapy of ultrasound-mediated NFkB-decoy transfer and transportal injection of paclitaxel, in mouse', International Journal of Cancer, vol. 122, no. 7, pp. 1645-1656. https://doi.org/10.1002/ijc.23280

Marked regression of liver metastasis by combined therapy of ultrasound-mediated NFkB-decoy transfer and transportal injection of paclitaxel, in mouse. / Azuma, Haruhito; Tomita, Naruya; Sakamoto, Takeshi; Kiyama, Satoshi; Inamoto, Teruo; Takahara, Kiyoshi; Kotake, Yatsugu; Segawa, Naoki; Morishita, Ryuichi; Takahara, Shiro; Hayasaki, Hana; Otsuki, Yoshinori; Horie, Shigeo; Tanigawa, Nobuhiko; Katsuoka, Yoji.

In: International Journal of Cancer, Vol. 122, No. 7, 01.04.2008, p. 1645-1656.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Marked regression of liver metastasis by combined therapy of ultrasound-mediated NFkB-decoy transfer and transportal injection of paclitaxel, in mouse

AU - Azuma, Haruhito

AU - Tomita, Naruya

AU - Sakamoto, Takeshi

AU - Kiyama, Satoshi

AU - Inamoto, Teruo

AU - Takahara, Kiyoshi

AU - Kotake, Yatsugu

AU - Segawa, Naoki

AU - Morishita, Ryuichi

AU - Takahara, Shiro

AU - Hayasaki, Hana

AU - Otsuki, Yoshinori

AU - Horie, Shigeo

AU - Tanigawa, Nobuhiko

AU - Katsuoka, Yoji

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Nuclear factor-kappaB (NFkB) plays a pivotal role in cancer progression. In this study, we developed a decoy cis-element oligodeoxyribonucleic acid against NFkB-binding site (NFkB-decoy), which effectively inhibits NFkB activity, and tested the effect of combined therapy comprising local transfection of NFkB-decoy into the liver and transportal injection of paclitaxel on cancer growth and metastasis using an orthotopic murine model of colon cancer liver metastasis. For NFkB-decoy transfection, we employed a novel approach using ultrasound exposure with an echocardiographic contrast agent, Optison. We examined the influence of NFkB-decoy transfer on susceptibility to paclitaxel in cancer cells and the mechanism involved using several in vitro analysis systems. We then studied the in vivo effect of combined NFkB-decoy transfer and paclitaxel in preventing cancer progression using a murine model of liver metastasis created by splenic injection of a human colon cancer cell line, HT29. In vitro experiments, including MTT-assay, fluorescence-activated cell sorter and cDNA array analysis, revealed that NFkB-decoy transfer significantly increased the susceptibility of cancer cells to paclitaxel, and that decreased expression of anti-apoptotic genes along with increased expression of genes relevant to the apoptosis-promotor may be involved. In vivo experiments showed that local transfection of NFkB-decoy into the liver followed by portal injection of paclitaxel effectively induced cancer cell apoptosis in the liver metastasis, and significantly prolonged animal survival compared to controls, without notable side effects. In conclusion, a combination of local NFkB-decoy transfer into the liver and transportal injection of paclitaxel may be a safe and effective new therapy for liver metastasis.

AB - Nuclear factor-kappaB (NFkB) plays a pivotal role in cancer progression. In this study, we developed a decoy cis-element oligodeoxyribonucleic acid against NFkB-binding site (NFkB-decoy), which effectively inhibits NFkB activity, and tested the effect of combined therapy comprising local transfection of NFkB-decoy into the liver and transportal injection of paclitaxel on cancer growth and metastasis using an orthotopic murine model of colon cancer liver metastasis. For NFkB-decoy transfection, we employed a novel approach using ultrasound exposure with an echocardiographic contrast agent, Optison. We examined the influence of NFkB-decoy transfer on susceptibility to paclitaxel in cancer cells and the mechanism involved using several in vitro analysis systems. We then studied the in vivo effect of combined NFkB-decoy transfer and paclitaxel in preventing cancer progression using a murine model of liver metastasis created by splenic injection of a human colon cancer cell line, HT29. In vitro experiments, including MTT-assay, fluorescence-activated cell sorter and cDNA array analysis, revealed that NFkB-decoy transfer significantly increased the susceptibility of cancer cells to paclitaxel, and that decreased expression of anti-apoptotic genes along with increased expression of genes relevant to the apoptosis-promotor may be involved. In vivo experiments showed that local transfection of NFkB-decoy into the liver followed by portal injection of paclitaxel effectively induced cancer cell apoptosis in the liver metastasis, and significantly prolonged animal survival compared to controls, without notable side effects. In conclusion, a combination of local NFkB-decoy transfer into the liver and transportal injection of paclitaxel may be a safe and effective new therapy for liver metastasis.

UR - http://www.scopus.com/inward/record.url?scp=39649089582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39649089582&partnerID=8YFLogxK

U2 - 10.1002/ijc.23280

DO - 10.1002/ijc.23280

M3 - Article

C2 - 18058816

AN - SCOPUS:39649089582

VL - 122

SP - 1645

EP - 1656

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -